RNA Transcriptome Profiling Test Market is Poised to Grow at a CAGR of 14.5% to Reach US$ 37,383.8 Million by 2034

The global RNA transcriptome profiling test market was worth US$ 7,923.3 million in 2023 and has been projected to grow at a commendable CAGR of 14.5% to reach US$ 37,383.8 million by 2034.

The RNA transcriptome profiling test market is a key part of the dynamic molecular biology areas that aim at in-depth investigations of the RNA transcripts within a tissue or cell. It contributes significantly towards understanding gene expression, biomarker identification, and, finally, personalized medicine.

For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=3113

During the forecast period of 2019-2023, the market for the RNA transcriptome profiling test expanded at a growth rate of 11.3%, and in 2023, it reached US$ 7,923.3 million. In the past, the RNA transcriptome profiling test market grew steadily because RNA sequencing technologies were improving continuously and research funding in the biomedical sector was increasing.

There was an upsurge in the need for precision medicine and biomarker identification, particularly for oncology and complex diseases.

Market Dynamics

Which are the Drivers Driving RNA Transcriptome Profiling Test Market Globally?
"Increased development of high-throughput sequencing technologies is the reason for the high demand of RNA transcriptome profiling test market"

RNA transcriptome profiling assays are becoming increasingly popular in large scale because of the new developments and innovations in high-throughput technologies. The challenge in analyzing the expressions of genes at the large scale with high efficiency and accuracy has reduced successfully because of the genomic research technology developments like next-generation sequencing (NGS).

These developments has resulted in delivering fast approaches for RNA profiling at reduced costs. These days, high-throughput technologies are more easily accessible to large numbers of researchers and clinical applications.

Country-wise Insights

The United States market stands at US$ 2,820.6 million in 2024 and is expected to grow at a CAGR of 14.5% until 2034. The United States market is expected to create an absolute opportunity of US$ 8,089.5 million between 2024 and 2034.

In China, the market for RNA transcriptome profiling testing is anticipated to expand at a CAGR of 15.5% during the period 2024-2034. It is estimated to be at the value of US$ 3,364.9 million by the end of 2034.

The U.S. takes the lead with robust programs like the Precision Medicine Initiative, which has driven genomic and transcriptomic research by integrating personalized healthcare solutions into the clinic. Players like Thermo Fisher Scientific have launched tools like the Ion Torrent Genexus System, streamlining NGS for clinical use and thus facilitating large-scale transcriptomic studies.

Category-wise Insights

High-throughput approaches are anticipated to create an absolute dollar opportunity of US$ 21,517.4 million. High-throughput approaches such as NGS and hybridization-based methods rule the RNA transcriptome profiling market owing to their ability to process large volumes of data with ease and a high level of precision.

These approaches can handle thousands of RNA samples in parallel, dramatically decreasing the analysis time and enabling large-scale research projects, including precision medicine and population genomics. Their depth and accuracy are central to the identification of low-abundance transcripts and new RNA species, essential to the understanding of diseases such as cancer and neurological disorders.

Browse Full Report: https://www.factmr.com/report/3113/rna-transcriptome-profiling-test-market

Competitive Landscape

Major players in the RNA transcriptome profiling test market include Agilent Technologies, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., Thermo Fisher Scientific, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., Pacific Biosciences of California, Inc., Eurofins Scientific, Merck KGaA, Promega Corporation, 10x Genomics, Twist Bioscience, Bruker Spatial Biology, and Cepheid among others.

In October 2024, Illumina, Inc. introduced its MiSeq i100 Series of sequencing platforms, offering unmatched benchtop speed and ease of use to drive the boundaries of next-generation sequencing (NGS) in laboratories.

In September 2024, introduced 100 new digital PCR (dPCR) assays for its QIAcuity platform for use in cancer studies, inherited genetic disease research, infectious disease surveillance, and food and environmental testing.

Pfizer and Thermo Fisher Scientific Inc. have signed a partnership agreement in May 2023 to facilitate the improvement of access to NGS-based testing at the local level for patients who have lung and breast cancers in more than 30 countries within Latin America, Africa, the Middle East, and Asia.

Agilent Technologies Inc. and South Korea's Theragen Bio partnered in April 2023 to collaborate on the complementary strengths of both firms on the design of cancer genomic profiling, engineering expertise and software background to propel the capabilities for localized analysis, thus accelerating treatment decisions.

Segmentation of RNA Transcriptome Profiling Test Industry Research
By Component Type :
Consumables
Reagents
Kits
Dyes
Instruments
RT PCR
Microarray
Sanger Sequencing Platform
RNA Sequencing Platform
Software
Services
By Method Type :
Conventional Methods
RNA-DNA Hybridization Measurements
Subtractive Hybridization
Differential Display
High Throughput Methods
Hybridization-based method using Micro Array Technology
Sequencing based
RNA sequencing
Serial analysis of gene expression (SAGE)
Massively Parallel Signature Sequencing (MPSS)
By Application :
Cancer Research
Complex Disease Biomarker Identification
Agrigenomics
RNA-Based Drug Response Biomarker Discovery
Others
By End User :
Hospital Based Laboratories
Diagnostic Centers
Academic and Research Institutes
Contract research Organizations (CROs)
Others
By Region :
North America
Latin America
Western Europe
Eastern Europe
East Asia
South Asia & Pacific
Middle East & Africa

Check out More Related Studies Published by Fact.MR:

CRISPR and Cas Genes Market
https://www.factmr.com/report/4823/crispr-and-cas-genes-market

Optical Preclinical Imaging Market
https://www.factmr.com/report/optical-preclinical-imaging-market

Pharmaceutical Coating Equipment Market
https://www.factmr.com/report/pharmaceutical-coating-equipment-market

Asthma Treatment Market
https://www.factmr.com/report/4422/asthma-treatment-market

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay competitive.

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.